Pre-clinical data demonstrated that inhibition of Cox2 synergizes with anti-PD-1 blockade in inducing eradication of tumors, implying that Cox2 inhibitors could be useful adjuvants for immune-based therapies in cancer patients (9). This evidence concerns the gene PTGS2 and cancer.